SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Renovo Plc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (12)10/25/2006 1:01:38 PM
From: keokalani'nui   of 40
 
A fast track application has recently been submitted to the FDA with a protocol for a pilot study of scar prevention following keloid excision. This is anticipated to be Renovo’s first trial in the United States.

To provide potential partners with an opportunity to contribute to protocol design of a large multinational series of scar revision trials (0060-0063) which are strategically important and expensive, Renovo has decided to slightly delay initiation of this set of trials until the first half of 2007, after a partnering deal is likely to have been concluded.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News